First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation June 19, 2026 -- Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-stage biop

A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.Researchers in Spain and Switzerland have identified an experimental molecule that may help restore the brain's natural defenses against Alzheimer's disease. The compound, known as OLE, appears to "reprogram" microglia, the brain's immune cells, allowing them to

June 20, 2026 -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward the New Drug Application (NDA) submission in the United States and brings new hope to millions of patients with cardiovascular and cerebrovascular diseases worldwide. Evategrel (CG-0255) is the leading asset developed f

June 22, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervou

Nura Bio, a neuroscience-focused biotech with a novel approach to treat disorders like amyotrophic lateral sclerosis (ALS), pulled in $73.8 million in a series B funding round to support two clinical programs that could potentially address neurological conditions with high unmet need. ALS, in particular, has been a daunting challenge for drugmakers. Only a select few, including Biogen’s Qalsody, have broken through to the market, leaving patients with limited options to treat a devastating and

Scientists at Baylor College of Medicine may have uncovered a promising new way to combat Alzheimer’s and Parkinson’s disease. Instead of trying to stop Tau and alpha-synuclein proteins from gathering into tiny droplets inside brain cells, the researchers found that tubulin—the protein that builds the cell’s internal transport network—can redirect these proteins away from forming toxic clumps and toward healthy, productive work.Scientists at Baylor College of Medicine have identified a potential

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment completed; follow‑up phase) and a Phase II study of the same combination as neoadjuvant treatment for EGFR-mutant resectable NSCLC. — Sac-TMT has been approved in China for advanced EGFR-mutant NSCLC foll

June 22, 2026 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of satricabtagene autoleucel ("satri-cel"), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesop

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig, Boehringer's immunoglobin G (IgG)-like bispecific T-cell engager, as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)1,2 Beamion LUNG-3 will explore HERNEXEOS® (z

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns These data will be highlighted in a late-breaking oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting June 14, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jayp